Compare Matson Inc (MATX) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Matson Inc vs Summit Therapeutics Inc — how do they compare? Matson Inc trades at $225.67 (market cap $6.81B), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 2× Matson Inc's market cap, and Matson Inc pays a 0.67% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Matson Inc for 23 Days and Summit Therapeutics Inc for 16 Days on average.
| MATX | SMMT | |
|---|---|---|
Market Cap | $6.81B | $13.71B |
Volume | 255,080 | 6,173,057 |
Sector | Industrials | Health |
52-Week High | $238.60 | $26.38 |
52-Week Low | $88.05 | $12.43 |
Typical Hold Time | 23 Days | 16 Days |
Enterprise Value | $7.41B | $13.04B |
Dividend Yield | 0.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Matson (MATX) trades at $225.67, up 1.23% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q2 2026 EPS of $4.27 beating estimates by 12.7% and raising full-year guidance. Revenue growth continues with 2026 projections of $3.5B and net profit margins above 13%. Recent institutional buying from Bank of New York Mellon and Deutsche Bank highlights confidence in the shipping company's prospects.
MATX presents a compelling investment case with strong earnings momentum, reasonable valuation (P/E 15.37), and positive analyst sentiment (67% buy ratings). Key risks include freight market cyclicality and competitive pressures. The stock's 27.3% upside potential based on analyst targets and consistent dividend payments ($0.38 declared for H2-26) support a favorable outlook for value-oriented investors seeking transportation sector exposure.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
